NHC CFO granted 1,507 restricted shares

National Healthcare Corp reported that SVP and CFO Brian F. Kidd acquired 1,507 shares of common stock on a grant or award basis at $0.00 per share.

Accepted by SEC EDGAR 03/03/2026 - 04:27 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

National Healthcare Corp reported that SVP and CFO Brian F. Kidd acquired 1,507 shares of common stock on a grant or award basis at $0.00 per share. Following this grant, his directly held common stock totals 25,224 shares.

The footnote explains these are restricted shares that vest over three years, with 33 1/3% vesting on 1/1/2027, another 33 1/3% on 1/1/2028, and the final 33 1/3% on 1/1/2029. The filing also lists existing options to purchase common stock held directly.

Insider Trade Summary

Grant/Award: 1,507 shares

Grant/Award 1 txn

Insider KIDD BRIAN F

Role SVP, CFO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,507	$0.00	$0.00
Holding	Option to Purchase Common Stock	--	--	--
Holding	Option to Purchase Common Stock	--	--	--
Holding	Option to Purchase Common Stock	--	--	--
Holding	Option to Purchase Common Stock	--	--	--

Holdings After Transaction: Common Stock — 25,224 shares (Direct); Option to Purchase Common Stock — 43,500 contracts (Direct)

Footnotes (1)

1. F1. Grant of restricted shares that are subject to a three-year vesting schedule with the first 33 1/3% vesting on 1/1/2027, the next 33 1/3% vesting on 1/1/2028, and the final 33 1/3% vesting on 1/1/2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NHC report for CFO Brian F. Kidd?

NHC reported that SVP and CFO Brian F. Kidd received a grant of 1,507 shares of common stock at $0.00 per share. These are restricted shares awarded as part of his compensation rather than open-market purchases.

How many NHC shares does CFO Brian F. Kidd own after this Form 4?

After the reported grant, Brian F. Kidd directly holds 25,224 shares of National Healthcare Corp common stock. This total reflects the newly awarded 1,507 restricted shares added to his existing directly owned holdings.

What is the vesting schedule for Brian F. Kidd’s 1,507 restricted NHC shares?

The 1,507 restricted shares vest in three equal installments of 33 1/3% each. Vesting dates are 1/1/2027, 1/1/2028, and 1/1/2029, meaning the award fully vests over a three-year period.

Did NHC’s CFO buy these 1,507 shares on the open market?

No. The filing shows the 1,507 shares as a grant or award acquisition at $0.00 per share. This indicates a compensation-related stock award, not an open-market purchase using personal funds.

What option holdings for NHC stock are listed for Brian F. Kidd?

The Form 4 lists several entries for options to purchase National Healthcare Corp common stock, all held directly. Reported post-transaction option holdings include lines showing 8,000, 13,500, and 14,000 options, reflecting existing equity-based compensation positions.

Does this NHC Form 4 show any insider stock sales by the CFO?

The Form 4 does not report any stock sales by the CFO. It records an acquisition of 1,507 restricted common shares through a grant and lists existing option holdings, without indicating any disposition transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KIDD BRIAN F

(Last) (First) (Middle)

100 VINE STREET

(Street)

MURFREESBORO TN 37130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NATIONAL HEALTHCARE CORP [ NHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		A		1,507(1)	A	$0	25,224	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$53.94							03/08/2024	03/08/2028	Common Stock	8,000		8,000	D
Option to Purchase Common Stock	$94.1							03/05/2025	03/05/2029	Common Stock	8,000		8,000	D
Option to Purchase Common Stock	$90.62							02/24/2026	02/24/2030	Common Stock	13,500		13,500	D
Option to Purchase Common Stock	$157.13							02/23/2027	02/23/2031	Common Stock	14,000		14,000	D

Explanation of Responses:

1. Grant of restricted shares that are subject to a three-year vesting schedule with the first 33 1/3% vesting on 1/1/2027, the next 33 1/3% vesting on 1/1/2028, and the final 33 1/3% vesting on 1/1/2029.

	/s/ Brian Kidd	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.